Showing 3851-3860 of 5646 results for "".
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- FDA Approves OnPoint Vision’s IDE Application to Begin Phase 1 of IOPCL Magnifierhttps://modernod.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/OnPoint Vision announced the FDA approval of their investigational device exemption (IDE) application to begin phase 1 of their pivotal clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with
- Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver comb
- FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481917/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The approval for RVO marks the third indication for Vabysmo, along with wet age-related macular degeneration (AMD) and diabetic macular edem
- Zeiss Expands its Clinical Workflows and Digital Portfolio at AAO 2023https://modernod.com/news/zeiss-expand-its-clinical-workflows-and-digital-portfolio-at-aao-2023/2481915/Zeiss Medical Technology will showcase digital enhancements to the cataract, corneal refractive, and retina workflows at the American Academy of Ophthalmology (AAO) conference from Nov. 4-6, 2023, in San Francisco. As part of the Zeiss Medical Ecosystem, these innovations offer new digital tools
- Bausch + Lomb Introduces New Surgical Planning Software for Eyetelligence Platformhttps://modernod.com/news/bausch-lomb-introduces-new-surgical-planning-software-for-eyetelligence-platform/2481907/Bausch + Lomb introduced new surgical planning software for the Eyetelligence platform designed to streamline surgical planning, information flow, and enable elect
- Stuart Therapeutics Enters License Agreement with Glaukos for Preclinical Glaucoma Drug Candidatehttps://modernod.com/news/stuart-therapeutics-enters-license-agreement-with-glaukos-for-preclinical-glaucoma-drug-candidate/2481904/Stuart Therapeutics has entered into a license agreement with Glaukos under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a pat
- The Lancet Publishes 24-Month Results from Phase 3 Studies of Syfovre for GAhttps://modernod.com/news/the-lancet-publishes-24-month-results-from-phase-3-studies-of-syfovre-for-geographic-atrophy/2481901/Apellis Pharmaceuticals announced that The Lancet has published 24-month results from the phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection)
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- FDA Finds 'Substantive' Issues in Aldeyra’s NDA for Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-finds-substantive-issues-in-aldeyras-reproxalap-drug-candidate-for-dry-eye-disease/2481895/Aldeyra Therapeutics was dealt a major setback this week as the FDA identified "substantive review issues" in the company’s new drug application for dry-eye disease treatment candidate reproxalap. In a US securities